SLC5A2 and diabetes mellitus: In the CVD‐REAL‐2 study, which focused on Asia Pacific, Middle Eastern and North American populations, significant reductions in all the aforementioned outcomes were noted in patients with diabetes treated with SGLT2 inhibitors compared with other glucose‐lowering therapies.20